Loading...
XSHE002737
Market cap1.57bUSD
Jan 15, Last price  
19.71CNY
1D
-1.35%
1Q
0.31%
Jan 2017
17.01%
IPO
36.26%
Name

Sunflower Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002737 chart
P/E
10.29
P/S
2.02
EPS
1.92
Div Yield, %
5.11%
Shrs. gr., 5y
-0.13%
Rev. gr., 5y
4.97%
Revenues
5.70b
+11.89%
1,559,003,6041,769,952,9912,180,932,0942,718,760,4823,034,770,4843,363,581,1083,855,119,8114,471,756,2774,371,413,6413,461,888,3474,460,899,8645,094,511,3195,700,286,745
Net income
1.12b
+29.05%
190,855,995234,241,117262,935,148301,127,653306,599,997303,015,572423,996,618563,277,153565,422,018584,454,186704,737,995867,222,0231,119,142,042
CFO
923m
-53.15%
257,602,550327,310,490293,341,828403,225,247125,840,223341,231,457558,770,770866,207,292981,327,6771,169,867,011865,229,4641,970,785,872923,300,476
Dividend
Jun 14, 20241.5 CNY/sh
Earnings
May 30, 2025

Profile

Sunflower Pharmaceutical Group Co.,Ltd researches, develops, manufactures, and markets Chinese patent medicines in China. The company also produces chemical, biological, and health care medicines. Its products are used in therapeutic areas, such as pediatrics, gynecology, digestive system, respiratory and cold, rheumatism and bone disease, and cardiovascular and cerebrovascular. The company sells its products under the Sunflower and Little Sunflower brands. Sunflower Pharmaceutical Group Co.,Ltd was founded in 2005 and is based in Harbin, China.
URL
https://www.kuihuayaoye.com/
IPO date
Dec 30, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,700,287
11.89%
5,094,511
14.20%
Cost of revenue
3,855,254
3,660,649
Unusual Expense (Income)
NOPBT
1,845,032
1,433,862
NOPBT Margin
32.37%
28.15%
Operating Taxes
189,831
171,406
Tax Rate
10.29%
11.95%
NOPAT
1,655,201
1,262,456
Net income
1,119,142
29.05%
867,222
23.06%
Dividends
(588,509)
(406,735)
Dividend yield
3.89%
3.00%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
14,433
425,586
Long-term debt
15,247
20,994
Deferred revenue
397,262
Other long-term liabilities
342,079
1
Net debt
(3,694,876)
(3,400,812)
Cash flow
Cash from operating activities
923,300
1,970,786
CAPEX
(149,165)
Cash from investing activities
36,199
Cash from financing activities
(1,038,830)
FCF
1,716,847
1,697,775
Balance
Cash
3,602,114
3,847,391
Long term investments
122,442
Excess cash
3,439,541
3,592,666
Stockholders' equity
3,789,161
3,793,736
Invested Capital
1,929,281
1,506,994
ROIC
96.34%
59.77%
ROCE
34.32%
28.06%
EV
Common stock shares outstanding
582,886
584,000
Price
25.98
12.08%
23.18
40.83%
Market cap
15,143,391
11.87%
13,537,120
41.54%
EV
11,689,761
10,370,304
EBITDA
2,026,236
1,702,672
EV/EBITDA
5.77
6.09
Interest
6,340
9,726
Interest/NOPBT
0.34%
0.68%